GENE ASSOCIATED WITH ARTERIOSCLEROTIC DISEASE, AND USE THEREOF

• US 20090324610A1
• Filed: 04/24/2007
• Published: 12/31/2009
• Est. Priority Date: 04/25/2006
• Status: Abandoned Application

• Current Assignee: Hisayama Research Institute For Lifestyle Diseases, Hubit Genomix Incorporated, Kyushu University, NTT Data Corporation (Nippon Telegraph and Telephone Corporation), University of Tokyo
• Original Assignee: Hisayama Research Institute For Lifestyle Diseases, Hubit Genomix Incorporated, Kyushu University, NTT Data Corporation (Nippon Telegraph and Telephone Corporation), The University of Tokyo
• Inventors: Iida, Mitsuo, Kubo, Michiaki, Ibayashi, Setsuro, Hata, Jun, Ichien, Go, Omae, Teruo, Kiyohara, Yutaka, Tanaka, Yasuhiro, Nakamura, Yusuke
• Application Number:
  US12/298,484
• Publication Number:
  US 20090324610A1
• Time in Patent Office: Days
• US Class Current: 424/158.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: G01N 2800/323 Arteriosclerosis, Stenosis
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/5023 on expression patterns
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes

Abstract

Two genes implicated in arteriosclerotic diseases such as cerebral infarction were successfully identified by performing genome-wide correlation studies using SNPs by targeting the entire genome. Polymorphic mutations that can be used to examine the presence or absence of risk factors for arteriosclerotic diseases were successfully found on the genes. Subjects can be efficiently examined for the presence or absence of risk factors for arteriosclerotic diseases using the presence or absence of the polymorphic mutations as indicators. Furthermore, methods of screening for therapeutic agents for arteriosclerotic diseases are enabled by using expression or function of the genes as index.

Claims

1. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, which uses the subject'"'"'s AGTRL1 gene expression as an index.

6. The method of any one of claims 1 to 5, wherein the mutation is a polymorphic mutation.

20. The method of any one of claims 1 to 19, wherein a biological sample derived from the subject is subjected to the test as a test sample.

2. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, which comprises detecting DNA mutation in the subject'"'"'s AGTRL1 gene.

3. The method of claim 2, wherein said mutation changes the binding of said gene with an Sp1 transcription factor.

4. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, which uses the subject'"'"'s PRKCH gene expression as an index.

5. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, which comprises detecting DNA mutation in the subject'"'"'s PRKCH gene.

7. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, wherein the method comprises determining type of nucleotide at a polymorphic site in the subject'"'"'s AGTRL1 gene.

8. The method of claim 7, wherein the polymorphic site is in the AGTRL1 gene located at (1a) position 1, (2a) position 12541, (3a) position 21545, (4a) position 33051, (5a) position 35365, (6a) position 39268, (7a) position 39353, (8a) position 39370, (9a) position 39474, (1a) position 39553, (11a) position 39665, (12a) position 41786, (13a) position 42019, (14a) position 42509, (15a) position 43029, (16a) position 43406, (17a) position 43663, (18a) position 46786, (19a) position 49764, (20a) position 64276, (21a) position 74482, (22a) position 78162, (23a) position 93492, or (24a) position 102938 of the nucleotide sequence of SEQ ID NO:

1.

9. The method of claim 8, wherein the subject is determined to have a risk factor for arteriosclerotic disease when the nucleotides at the polymorphic sites of (1a) to (24a) of claim 8 are (1b) to (24b) below, respectively:

(1b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 1 of the nucleotide sequence of SEQ ID NO;

1 is T;

(2b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 12541 of the nucleotide sequence of SEQ ID NO;

1 is T;

(3b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 21545 of the nucleotide sequence of SEQ ID NO;

1 is A;

(4b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 33051 of the nucleotide sequence of SEQ ID NO;

1 is C;

(5b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 35365 of the nucleotide sequence of SEQ ID NO;

1 is T;

(6b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 39268 of the nucleotide sequence of SEQ ID NO;

1 is A;

(7b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 39353 of the nucleotide sequence of SEQ ID NO;

1 is G;

(8b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 39370 of the nucleotide sequence of SEQ ID NO;

1 is C;

(9b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 39474 of the nucleotide sequence of SEQ ID NO;

1 is T;

(10b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 39553 of the nucleotide sequence of SEQ ID NO;

1 is T;

(11b) the nucleotide in the AGTRL1 gene located at position 39665 of the nucleotide sequence of SEQ ID NO;

1 has been deleted;

(12b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 41786 of the nucleotide sequence of SEQ ID NO;

1 is A;

(13b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 42019 of the nucleotide sequence of SEQ ID NO;

1 is G;

(14b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 42509 of the nucleotide sequence of SEQ ID NO;

1 is G;

(15b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 43029 of the nucleotide sequence of SEQ ID NO;

1 is G;

(16b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 43406 of the nucleotide sequence of SEQ ID NO;

1 is C;

(17b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 43663 of the nucleotide sequence of SEQ ID NO;

1 is T;

(18b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 46786 of the nucleotide sequence of SEQ ID NO;

1 is C;

(19b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 49764 of the nucleotide sequence of SEQ ID NO;

1 is T;

(20b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 64276 of the nucleotide sequence of SEQ ID NO;

1 is T;

(21b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 74482 of the nucleotide sequence of SEQ ID NO;

1 is C;

(22b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 78162 of the nucleotide sequence of SEQ ID NO;

1 is G;

(23b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 93492 of the nucleotide sequence of SEQ ID NO;

1 is G; and

(24b) the type of nucleotide in the complementary strand of the AGTRL1 gene located at position 102938 of the nucleotide sequence of SEQ ID NO;

1 is C.

10. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, wherein the subject is determined to have a risk factor for arteriosclerotic disease when a DNA block showing the following haplotype is detected:

(A) a haplotype in which the nucleotides in the complementary strand of the AGTRL1 gene at polymorphic sites located at positions 39268, 39353, 41786, 42019, and 43406 of the nucleotide sequence of SEQ ID NO;

1 are A, G, A, G, and C, respectively.

11. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, which comprises the step of determining the type of nucleotide of a linked polymorphic site present within a DNA block showing the following haplotype:

(A) a haplotype in which the nucleotides of the complementary strand at polymorphic sites on the AGTRL1 gene located at positions 39268, 39353, 41786, 42019, and 43406 of the nucleotide sequence of SEQ ID NO;

1 are A, G, A, G, and C, respectively.

12. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, which comprises the steps of:

(a) determining the type of nucleotide at a polymorphic site in the AGTRL1 gene of the subject; and

(b) determining that the subject has a risk factor for arteriosclerotic disease when the nucleotide determined in (a) is the same as the nucleotide at said polymorphic site in the AGTRL1 gene showing the haplotype of (A);

(A) a haplotype in which the nucleotides of the complementary strand at polymorphic sites in the AGTRL1 gene located at positions 39268, 39353, 41786, 42019, and 43406 of the nucleotide sequence of SEQ ID NO;

1 are A, G, A, G, and C, respectively.

13. The method of claim 12, wherein said polymorphic site of (a) is in the AGTRL1 gene located at any one of positions 1, 12541, 21545, 33051, 35365, 39268, 39353, 39370, 39474, 39553, 39665, 41786, 42019, 42509, 43029, 43406, 43663, 46786, 49764, 64276, 74482, 78162, 93492, or 102938 of the nucleotide sequence of SEQ ID NO:

1.

14. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, wherein the subject is determined to have a risk factor for arteriosclerotic disease when the expression level of the subject'"'"'s AGTRL1 gene is elevated compared to that of a control.

15. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, wherein the method comprises determining the type of nucleotide at a polymorphic site in the subject'"'"'s PRKCH gene.

16. The method of claim 15, wherein the polymorphic site is in the PRKCH gene located at (1a) position 1, (2a) position 16212, (3a) position 30981, (4a) position 32408, (5a) position 33463, (6a) position 34446, (7a) position 39322, (8a) position 39469, (9a) position 39471, (10a) position 49248, (11a) position 49367, or (12a) position 52030 of the nucleotide sequence of SEQ ID NO:

2.

17. The method of claim 16, wherein the subject is determined to have a risk factor for arteriosclerotic disease when the nucleotides in the polymorphic sites of (1a) to (12a) of claim 16 are the following (1b) to (12b), respectively:

(1b) the nucleotide in the PRKCH gene located at position 1 of the nucleotide sequence of SEQ ID NO;

2 is A;

(2b) the nucleotide in the PRKCH gene located at position 16212 of the nucleotide sequence of SEQ ID NO;

2 is G;

(3b) the nucleotide in the PRKCH gene located at position 30981 of the nucleotide sequence of SEQ ID NO;

2 is A;

(4b) the nucleotide in the PRKCH gene located at position 32408 of the nucleotide sequence of SEQ ID NO;

2 is G;

(5b) the nucleotide in the PRKCH gene located at position 33463 of the nucleotide sequence of SEQ ID NO;

2 is G;

(6b) the nucleotide in the PRKCH gene located at position 34446 of the nucleotide sequence of SEQ ID NO;

2 is T;

(7b) the nucleotide in the PRKCH gene located at position 39322 of the nucleotide sequence of SEQ ID NO;

2 is T;

(8b) the nucleotide in the PRKCH gene located at position 39469 of the nucleotide sequence of SEQ ID NO;

2 is A;

(9b) the nucleotide in the PRKCH gene located at position 39471 of the nucleotide sequence of SEQ ID NO;

2 is C;

(10b) the nucleotide in the PRKCH gene located at position 49248 of the nucleotide sequence of SEQ ID NO;

2 is C;

(11b) the nucleotide in the PRKCH gene located at position 49367 of the nucleotide sequence of SEQ ID NO;

2 is G; and

(12b) the nucleotide in the PRKCH gene located at position 52030 of the nucleotide sequence of SEQ ID NO;

2 is A.

21. A reagent for testing for the presence or absence of a risk factor for arteriosclerotic disease, which comprises an oligonucleotide that hybridizes with a DNA comprising the polymorphic sites of (1a) to (24a) of claim 8 or (1a) to (12a) of claim 16 and has a length of at least 15 nucleotides.

22. A reagent for testing for the presence or absence of a risk factor for arteriosclerotic disease, which comprises a solid phase to which a nucleotide probe is immobilized, wherein the nucleotide probe hybridizes with a DNA comprising the polymorphic sites of (1a) to (24a) of claim 8 or (1a) to (12a) of claim 16.

23. A reagent for testing for the presence or absence of a risk factor for arteriosclerotic disease, which comprises a primer oligonucleotide for amplifying a DNA comprising the polymorphic sites of (1a) to (24a) of claim 8 or (1a) to (12a) of claim 16.

18. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, wherein the subject is determined to have a risk factor for arteriosclerotic disease when the autophosphorylation activity or kinase activity of the subject'"'"'s PRKCH protein is elevated compared to that of a control.

19. A method for testing whether or not a subject has a risk factor for arteriosclerotic disease, wherein the subject is determined to have a risk factor for arteriosclerotic disease when the subject carries a mutant protein in which valine at position 374 in the amino acid sequence of the PRKCH protein is substituted with isoleucine.

24. A reagent for testing for the presence or absence of a risk factor for arteriosclerotic disease, which comprises (a) or (b) as an active ingredient:

(a) an oligonucleotide that hybridizes with a transcript of an AGTRL1 or PRKCH gene; and

(b) an antibody that recognizes an AGTRL1 or PRKCH protein.

25. A reagent for screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises any one of (a) to (c) as an active ingredient:

(a) an oligonucleotide that hybridizes with a transcript of an AGTRL1 gene;

(b) an antibody that recognizes an AGTRL1 protein; and

(c) a polynucleotide comprising a DNA region which comprises a nucleotide site in a AGTRL1 gene located at position 39353 or 42509 of the nucleotide sequence of SEQ ID NO;

1.

26. A reagent for screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises any one of (a) to (c) as an active ingredient:

(a) an oligonucleotide that hybridizes with a transcript of a PRKCH gene;

(b) an antibody that recognizes a PRKCH protein; and

(c) a mutant PRKCH protein which has an amino acid sequence in which valine at position 374 of the amino acid sequence of a PRKCH protein is substituted with isoleucine.

27. A pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises as an active ingredient a substance that suppresses the expression of an AGTRL1 or PRKCH gene or suppresses the function of a protein encoded by said gene.

28. The pharmaceutical agent of claim 27, wherein the substance that suppresses the expression of the AGTRL1 or PRKCH gene is a compound selected from the group consisting of (a) to (c):

(a) an antisense nucleic acid against a transcript of the AGTRL1 or PRKCH gene or a portion thereof;

(b) a nucleic acid having a ribozyme activity of specifically cleaving a transcript of the AGTRL1 or PRKCH gene; and

(c) a nucleic acid having an effect of inhibiting the expression of the AGTRL1 or PRKCH gene through an RNAi effect.

29. The pharmaceutical agent of claim 27, wherein the substance that suppresses the function of the AGTRL1 or PRKCH protein is the compound of (a) or (b):

(a) an antibody that binds to an AGTRL1 or PRKCH protein;

or

(b) a low-molecular-weight compound that binds to an AGTRL1 or PRKCH protein.

30. A pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises as an active ingredient a substance that inhibits the binding of an Sp1 transcription factor with a DNA region that comprises a nucleotide site in the AGTRL1 gene located at position 39353 or 42509 of the nucleotide sequence of SEQ ID NO:

1.

31. A pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises as an active ingredient a substance that inhibits the autophosphorylation activity of a PRKCH protein.

32. A method of screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises selecting a compound that reduces the expression level of an AGTRL1 or PRKCH gene or reduces the activity of a protein encoded by said gene.

35. The method of any one of claims 32 to 34, wherein the AGTRL1 gene is a mutant AGTRL1 gene of (a) or (b) whose expression is enhanced:

(a) a mutant AGTRL1 gene in which the nucleotide in the complementary strand of the AGTRL1 gene located at position 42509 of the nucleotide sequence of SEQ ID NO;

1 is G;

or

(b) a mutant AGTRL1 gene in which the nucleotide in the complementary strand of the AGTRL1 gene located at position 39353 of the nucleotide sequence of SEQ ID NO;

1 is G.

33. A method of screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises the steps of:

(a) contacting a test compound with a cell that expresses an AGTRL1 or PRKCH gene;

(b) measuring the expression level of said AGTRL1 or PRKCH gene; and

(c) selecting the compound that reduces the expression level as compared with that measured in the absence of the test compound.

34. A method of screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises the steps of:

(a) contacting a test compound with a cell or cell extract that comprises a DNA having a structure in which a transcriptional regulatory region of an AGTRL1 or PRKCH gene and a reporter gene are operably linked with each other;

(b) measuring the expression level of said reporter gene; and

(c) selecting a compound that reduces said expression level as compared with that measured in the absence of the test compound.

36. A method of screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises the steps of:

(a) contacting a test compound with an Sp1 transcription factor and a polynucleotide comprising a DNA region that comprises a nucleotide site in an AGTRL1 gene located at position 39353 or 42509 of the nucleotide sequence of SEQ ID NO;

1;

(b) measuring the binding activity between said polynucleotide and the Sp1 transcription factor; and

(c) selecting a compound that reduces said binding activity as compared with that measured in the absence of the test compound.

37. A method of screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises the steps of:

(a) contacting a test compound with a PRKCH protein;

(b) measuring the autophosphorylation activity of the PRKCH protein; and

(c) selecting a compound that reduces the autophosphorylation activity as compared with that measured in the absence of the test compound.

38. The method of claim 37, wherein said PRKCH protein is a mutant protein in which valine of position 374 in the amino acid sequence of the PRKCH protein is substituted with isoleucine.

39. A method of screening for a pharmaceutical agent for treating or preventing arteriosclerotic disease, which comprises the steps of:

(a) contacting a test compound with a PRKCH protein;

(b) measuring the protein kinase activity of the PRKCH protein; and

(c) selecting a compound that reduces the protein kinase activity as compared with that measured in the absence of the test compound.